---
figid: PMC8223777__cells-10-01270-g002
figtitle: 'Mast Cells: A New Frontier for Cancer Immunotherapy'
organisms:
- Homo sapiens
- Mus musculus
- Canis lupus familiaris
- Severe acute respiratory syndrome coronavirus 2
- Trichinella spiralis
organisms_ner:
- Mus musculus
- Canis lupus familiaris
- Homo sapiens
- Danio rerio
pmcid: PMC8223777
filename: cells-10-01270-g002.jpg
figlink: /pmc/articles/PMC8223777/figure/cells-10-01270-f002/
number: F2
caption: Therapeutic strategies to target mast cells for cancer immunotherapy. Mast
  cells can be therapeutically targeted by (1) decreasing cell numbers through c-KIT
  inhibition, (2) modulating mast cell activation and phenotype (through mast cell
  stabilizers, FcεR1 signaling pathway activators/inhibitors, antibodies targeting
  inhibitory receptors and ligands, TLR agonists), and (3) altering secreted mast
  cell mediators and their downstream effects. c-KIT, tyrosine protein kinase KIT
  or CD117; SYK, spleen tyrosine kinase; PI3K, phosphoinositide 3-kinase; BTK, Bruton’s
  tyrosine kinase; SHIP-1, Src homology 2 domain containing inositol polyphosphate
  5-phosphatase 1; SIGLEC-8, sialic acid-binding Ig-like lectin 8; FcγRIIB, Fc gamma
  receptor IIB; PD-L1, programmed death ligand 1; TLR, toll-like receptor; TNF-α,
  tumor necrosis factor alpha; H1R-H4R, histamine 1–4 receptor; FcεR1, high-affinity
  IgE receptor or Fc epsilon receptor 1; IgE, immunoglobulin E.
papertitle: 'Mast Cells: A New Frontier for Cancer Immunotherapy.'
reftext: Jake N. Lichterman, et al. Cells. 2021 Jun;10(6):1270.
year: '2021'
doi: 10.3390/cells10061270
journal_title: Cells
journal_nlm_ta: Cells
publisher_name: MDPI
keywords: mast cell | cancer | immunotherapy | microenvironment | cancer immunology
  | c-KIT | TLR | toll-like receptors
automl_pathway: 0.8937768
figid_alias: PMC8223777__F2
figtype: Figure
redirect_from: /figures/PMC8223777__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8223777__cells-10-01270-g002.html
  '@type': Dataset
  description: Therapeutic strategies to target mast cells for cancer immunotherapy.
    Mast cells can be therapeutically targeted by (1) decreasing cell numbers through
    c-KIT inhibition, (2) modulating mast cell activation and phenotype (through mast
    cell stabilizers, FcεR1 signaling pathway activators/inhibitors, antibodies targeting
    inhibitory receptors and ligands, TLR agonists), and (3) altering secreted mast
    cell mediators and their downstream effects. c-KIT, tyrosine protein kinase KIT
    or CD117; SYK, spleen tyrosine kinase; PI3K, phosphoinositide 3-kinase; BTK, Bruton’s
    tyrosine kinase; SHIP-1, Src homology 2 domain containing inositol polyphosphate
    5-phosphatase 1; SIGLEC-8, sialic acid-binding Ig-like lectin 8; FcγRIIB, Fc gamma
    receptor IIB; PD-L1, programmed death ligand 1; TLR, toll-like receptor; TNF-α,
    tumor necrosis factor alpha; H1R-H4R, histamine 1–4 receptor; FcεR1, high-affinity
    IgE receptor or Fc epsilon receptor 1; IgE, immunoglobulin E.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Kit
  - Fcer1a
  - Ms4a2
  - Fcer1g
  - Syk
  - Pik3r1
  - Btk
  - Inpp5d
  - Cd274
  - Tlr2
  - Tlr7
  - Tlr4
  - Spg21
  - Spaca9
  - Tnf
  - KIT
  - SYK
  - BTK
  - CD274
  - TLR2
  - TLR7
  - TLR4
  - TNF
  - FCER1A
  - MS4A2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - INPP5D
  - SIGLEC8
  - TLR1
  - TLR3
  - TLR5
  - TLR6
  - TLR8
  - TLR9
  - TLR10
  - SPACA9
  - SPG21
  - IGHE
  - ERVK-8
  - ERVK-10
  - ERVK-9
  - ERVK-21
  - ERVK-18
  - ERVK-25
  - ERVK-24
  - ERVK-19
  - CMA1
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - CXCL10
  - CXCL11
  - CXCL12
  - CXCL13
  - CXCL14
  - CXCL9
  - PF4
  - CXCL1
  - CXCL2
  - CXCL3
  - CXCL5
  - CXCL6
  - CXCL8
  - PPBP
  - kita
  - syk
  - btk
  - ngfra
  - si:ch211-241b2.5
  - tlr2
  - tlr7
  - tnfa
  - tnfb
---
